Compare AEE & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEE | WST |
|---|---|---|
| Founded | 1901 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5B | 20.2B |
| IPO Year | N/A | N/A |
| Metric | AEE | WST |
|---|---|---|
| Price | $97.44 | $266.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $109.91 | ★ $346.78 |
| AVG Volume (30 Days) | ★ 1.7M | 635.1K |
| Earning Date | 11-05-2025 | 10-23-2025 |
| Dividend Yield | ★ 2.92% | 0.33% |
| EPS Growth | ★ 22.35 | 0.17 |
| EPS | 5.21 | ★ 6.75 |
| Revenue | ★ $8,635,000,000.00 | $3,017,900,000.00 |
| Revenue This Year | $14.17 | $7.01 |
| Revenue Next Year | $5.69 | $6.20 |
| P/E Ratio | ★ $18.68 | $39.63 |
| Revenue Growth | ★ 23.25 | 4.92 |
| 52 Week Low | $86.40 | $187.43 |
| 52 Week High | $106.73 | $348.90 |
| Indicator | AEE | WST |
|---|---|---|
| Relative Strength Index (RSI) | 27.78 | 45.27 |
| Support Level | $100.34 | $263.38 |
| Resistance Level | $106.61 | $274.56 |
| Average True Range (ATR) | 1.59 | 7.32 |
| MACD | -0.73 | -0.79 |
| Stochastic Oscillator | 7.47 | 15.52 |
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and 800,000 natural gas customers across its two service territories.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.